We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) ACLASTA zoledronic acid 5 mg/100 mL solution for injection (France)
Section 19A approved medicine
(Approval lapsed) ACLASTA zoledronic acid 5 mg/100 mL solution for injection (France)
Section 19A approval holder
Sandoz Pty Ltd ABN 60 754 449 553
Phone
1800 726 369
Approved until
Status
Expired
Medicines in short supply/unavailable
ACLASTA zoledronic acid 5mg/100mL injection solution vial - ARTG 134664 and OSTEOVAN zoledronic acid 5mg/100mL injection solution vial - ARTG 134665
Indication(s)
- Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures.
- Treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures.
- To increase bone mineral density in men with osteoporosis.
- To increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use.
- To prevent glucocorticoid-induced bone mineral density loss.
- Treatment of Paget's disease of bone.
Images
